0.05Open0.05Pre Close0 Volume142 Open Interest2.50Strike Price0.00Turnover604.54%IV152.48%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1745Delta0.3623Gamma20.20Leverage Ratio-0.0179Theta0.0000Rho3.53Eff Leverage0.0003Vega
Cytosorbents Stock Discussion
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
CytoSorbents (NASDAQ: CTSO) and Converge Biotech have announced a strategic partnership to expand their market reach in India's sepsis and critical care markets. CytoSorbents' flagship product, CytoSorb, a blood purification technology that reduces cytokine storm and inflammatory toxins, will be distributed through Converge Biotech's ext...
📊⚡️📊
NEWS
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
No comment yet